10 Best Breakout Stocks to Invest In

6. CorMedix Inc. (NASDAQ:CRMD)

Share Price as of November 14: $11.62

200-Day Simple Moving Average: $11.17

Relative Volume: 2.91

Number of Hedge Fund Holders: 29

CorMedix Inc. (NASDAQ:CRMD) is one of the best breakout stocks to invest in. On November 13, H.C. Wainwright’s Brandon Folkes reaffirmed a Buy on CorMedix Inc. (NASDAQ:CRMD), citing strong DefenCath-driven revenue, Melinta acquisition synergies, and multiple growth catalysts including Rezzayo and TPN Phase 3 data in 2026. Despite TDAPA pricing risks, robust financials and pipeline potential support a favorable long-term outlook.

On November 12, CorMedix Inc. delivered strong third-quarter results, underscoring demand for specialty injectable therapies. It posted $104.3 million in net revenue and $130.8 million in pro forma net revenue, driven by higher utilization of DefenCath by outpatient dialysis customers.

Likewise, the company bounced back to profitability, generating $108.6 million in net income, or $1.26 per share. It was an improvement from a net loss of $2.8 million, or $0.05 per share, delivered in the same quarter last year.  Growth in net income was driven by net product sales and a one-time tax benefit of $59.7 million.

CorMedix is betting on DefenCath, an FDA-approved catheter lock solution that offers significant risk reduction in catheter-related bloodstream infections (CRBSI). Consequently, it has raised its full-year 2025 pro forma net revenue to between $390 million and $410 million. It also expects net revenue to range between $115 million and $135 million. Following the acquisition of Melinta Therapeutics, the company expects to capture $30 million in synergy.

CorMedix Inc. (NASDAQ:CRMD) is a biopharmaceutical company focused on developing and commercializing therapeutic products for infectious and inflammatory diseases. Its lead product is DefenCath, an antimicrobial catheter lock solution used to prevent catheter-related bloodstream infections in hemodialysis patients.